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Transcriptional Response Pathways in a Yeast Strain
Sensitive to Saframycin A and a More Potent Analog:
Evidence for a Common Basis of Activity
trials for cancer therapy [14–17], has also been shown
to alkylate G residues of duplex DNA [18]. For both
natural products, compelling evidence has been offered
to support the involvement of an iminium ion intermedi-
ate in this process (this intermediate is formed by the
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Cambridge, Massachusetts 02138 expulsion of cyanide in the case of SafA and water in
the case of Et-743) [19]. Proposals concerning the mech-
anism of action of SafA have focused on DNA as a
primary target, perhaps in association with one or moreSummary
cellular proteins. Experiments designed to evaluate the
mechanism of action of Et-743 have investigated theSaframycin A (SafA) is a natural product that inhibits
human cancer cell proliferation. Its synthetic analog, possible involvement of ternary complexes of drug,
DNA, and transcription factors [20–22], as well as drug,QAD, is a more potent inhibitor of these cells. SafA
does not affect wild-type yeast, but it does inhibit DNA, and an excision-repair protein [23, 24]. Recently,
Et-743 and the equipotent synthetic analog Pt-650 [25]growth of the strain CCY333 (PDR1/PDR3/ERG6)
(IC50  0.9 M). QAD is also a more effective inhibitor have been subjected to comparative analysis by tran-
scription-profiling experiments in human cancer cellsof CCY333 growth (IC50  0.4M). Transcription profil-
ing of SafA- and QAD-treated CCY333 cultures [26]. It has not been established that SafA and Et-743
have a common basis of activity.showed that both drugs generated nearly identical
profiles, with altered expression levels (2-fold) of As a result of an extensive program leading to the
development of an efficient laboratory synthetic routemore than 240 genes. Both agents induced the overex-
pression of genes involved in glycolysis, oxidative to SafA [27], we have synthesized a large number of
SafA structural analogs, many of which were more po-stress, and protein degradation and repressed genes
encoding histones, biosynthetic enzymes, and the cel- tent than SafA itself [28]. The analog QAD, which is
modified by replacement of the pyruvamide side chainlular import machinery. Significantly, neither drug af-
fected the expression of known DNA-damage repair of SafA with a quinaldic acid amide residue and by
transformation of the two quinone rings of SafA to hydro-genes, as might have been expected if their primary
mechanism of action involved the covalent modifica- quinone methyl ethers, is one of the more potent com-
pounds we have discovered. The compound QADtion of DNA.
showed 30-fold greater activity versus SafA in a lung
carcinoma cell line (A549) and 4-fold greater activity inIntroduction
a melanoma cell line (A375) [28]. QAD has been reported
to show 100-fold greater potency versus Et-743 in threeSaframycin A (SafA) is a structurally complex natural
product ([1, 2]; Figure 1) that inhibits the growth of hu- human sarcoma cell lines (Joseph Bertino and Wei Wei
Li, Memorial Sloan-Kettering Cancer Center, personalman cancer cells at extremely low doses in culture (mean
GI50 values, 0.3–12 nM; NCI human tumor cell line screen, communication). In light of the substantial structural
modification of QAD relative to SafA and its greaterfour data sets) [3, 4]. The basis for the antiproliferative
activity of SafA has not been established, although im- potency, the question arose as to whether activity-
directed lead optimization had produced an agent thatportant experiments directed toward an understanding
of its mechanism of action have been conducted. In acted by the same mechanism as the natural product.
Whole-genome transcription profiling of yeast providesearly work, Ishiguro et al. [5] showed that treatment of
cultured L1210 leukemia cells with SafA (IC50, 5.6 nM a powerful tool for monitoring changes in expression
[6]) led to diminished incorporation of [3H]-uridine into levels of genes in a simple eukaryotic organism in re-
nucleolar and nucleoplasmic RNA. In addition, newly sponse to a given stimulus [29–34], and it potentially
synthesized (3H-labeled) RNA from both fractions was offers a means for the comprehensive comparison of
found to be of shorter length. Both effects were amplified the effects of two different small-molecule agents in vivo
as the concentration of SafA was increased. SafA was and provides insight into the pathways that are affected
also shown to inhibit the template activity of DNA in the [35, 36]. The yeast genome has been fully sequenced,
presence of a reducing agent such as dithiothreitol; such and a large number of yeast gene products have been
an activity is associated with the ability of SafA to alkyl- characterized with regard to function. Although wild-
ate the exocyclic amino group of guanine residues in type yeast is not susceptible to growth inhibition by
double-stranded DNA after reductive activation [5, 7– SafA, an ERG6/PDR1/PDR3 deletant (strain CCY333;
11]. The DNA-alkylation reaction has been demon- yeast mutants bearing these deletions were previously
strated to be reversible and specific for duplex DNA; prepared in the laboratories of Professor Julian Simon,
single-stranded DNA does not form a stable SafA alkyl- Fred Hutchinson Cancer Research Center. The CCY333
ation product. The structurally related alkaloid ecteinas- yeast strain was constructed by Dr. Christina Cuomo
cidin-743 (Et-743) [12, 13], currently in advanced clinical [Harvard University] in the laboratories of Professor An-
drew Murray [Christina Cuomo, personal communica-
tion]; [37]) was found to be sensitive to growth inhibition1Correspondence: myers@chemistry.harvard.edu
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Figure 2. Number of Genes Overexpressed or Repressed 2-Fold
Relative to Controls at 30 and 60 Minute Time Points after Treatment
with SafA or QAD
at which 30% inhibition of growth was observed, insuffi-
cient mRNA was isolated by this method for meaningful
hybridization experiments.
A greater transcriptional response to drug treatment
was detected in hybridizations to DNA microarrays with
Figure 1. Structures of Saframycin A, the More Potent Quinaldic cDNA synthesized by an alternative technique that did
Acid Derivative, and Ecteinascidin-743.
not require the isolation of mRNA [40]. In this procedure,
Saframycin A, SafA; quinaldic acid derivative, QAD; ecteinascidin- cDNA was prepared from a sample of total RNA by
743, Et-743.
reverse transcription with oligo(dT) primers to selec-
tively hybridize to the polyA tail of mRNA. As in the prior
method, no meaningful hybridization data were obtainedby both SafA and QAD and was therefore selected for
after 60 min, presumably because of diminished mRNAwhole-genome transcription profiling experiments.
levels. Because a greater transcriptional response was
detected, all subsequent microarray hybridizations wereResults
performed with fluorescently labeled cDNAs prepared
from total RNA, and analysis was restricted to timeIdentification of a Yeast Strain Sensitive to SafA
points early in the incubation (60 min). Except as noted,and QAD and Growth-Inhibition Studies
the analysis below refers to experiments conducted withGrowth of S. cerevisiae strain BY4743 was found to be
60 min drug exposure.unaffected in the presence of SafA or QAD at concentra-
tions as high as 1 mM, confirming previous reports [1].
Transcriptional Responses of Yeast StrainIn contrast, growth of the weakened strain CCY333 was
CCY333 to SafA and QAD: A
greatly inhibited in the presence of either SafA or QAD.
Genome-Wide Analysis
This strain lacks ERG6, a gene required for the biosyn-
Exposure of the mutant yeast strain CCY333 to either
thesis of ergosterol (affecting membrane permeability) SafA or QAD produced a large transcriptional response;
[38], and the genes PDR1 and PDR3, encoding transcrip- expression levels of more than 240 genes were modified
tion factors that regulate the expression of genes associ- by 2-fold. After 60 min, treatment with SafA led to
ated with multidrug resistance [39]. Control experiments 2-fold-enhanced expression of 130 genes (33 of un-
showed that in the absence of drug, cultures of the known function) and decreased the expression of 110
weakened strain grew well, with a doubling time of 2 genes 2-fold (27 of unknown function) relative to non-
hr. Growth-inhibition studies conducted in the presence treated controls, whereas treatment with QAD led to
of SafA and QAD established IC50 values of 0.9 M and 2-fold-enhanced expression of 115 genes (31 of un-
0.4 M, respectively. Thus, the sensitivity to drug treat- known function) and decreased the expression of 125
ment in the weakened strain is at least 1000-fold greater genes2-fold (28 of unknown function, Figure 2). Genes
than the laboratory strain BY4743. In light of its greater overexpressed 2-fold in both the SafA and QAD ex-
sensitivity to both SafA and QAD, all subsequent experi- pression profiles and those repressed 2-fold in both
ments were conducted with the yeast strain CCY333. profiles were strongly correlated (Figure 3A, P-values
1.0  1040). There was virtually no overlap of genes
Drug Treatment Leads to mRNA Depletion; cDNA overexpressed by one agent (SafA or QAD, 1.7-fold)
Preparation for Microarray Analysis and repressed by the other (1.0-fold, Figure 3B). The
Quantification by UV absorption at 260 nm of mRNA statistical correlation between the gene expression data
isolated by the use of an oligo(dT) resin from cultures sets at 60 min was 0.87 (Figure 4). At 30 min, fewer genes
of yeast strain CCY333 treated with SafA or QAD (10 were transcriptionally modified by drug treatment, and
M) showed that rapid diminution in mRNA levels oc- the statistical correlation between the data sets was
curred over the course of the 2 hr incubation (three lower (0.72).
independent experiments). At 1 hr, a point at which
growth inhibition was not yet evident, sufficient mRNA Analysis of Genes Overexpressed in Both SafA
was isolated to synthesize fluorescently labeled cDNA and QAD Expression Profiles
(by the use of random hexamer DNA primers) for subse- Genes overexpressed 2-fold after exposure of the
yeast strain CCY333 to SafA or QAD (60 min) can bequent hybridization to a DNA microarray. At 2 hr, a point
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proteins involved in the transport of intracellular material
to the vacuole (autophagocytosis) and proteases in-
volved in vacuolar protein degradation.
Proteins Associated with Oxidative-Stress
Response
In this category, genes overexpressed included those
encoding Cu/Zn and Mn superoxide dismutase (SOD1
and SOD2), thioperoxidases (TSA1, AHP1, and
YBL064C), thioredoxins (TRX1 and TRX2), and glutathi-
one peroxidase (HYR1).
Proteins Associated with Other Stress Responses
In addition to genes associated with oxidative-stress
response, genes encoding heat-shock proteins, and
genes encoding proteins required for protein refolding
(cyclophilins CPR3, CPR6, CYP5, CYP2, and nuclear
isomerases FPR1 and FPR3), were overexpressed.
Proteins Involved in the Synthesis and Processing
of RNA
Genes overexpressed in this category were HRP1, en-
coding a protein involved in mRNA processing [41], and
SBP1, encoding a protein that is essential for ribosomal
RNA processing [42].
Figure 3. Venn Diagrams Comparing Gene Overexpression by SafA
DNA Damage-Responsive Genesand QAD
Expression of RNR2 and RNR4, components of ribonu-Venn diagrams comparing (A) sets of genes overexpressed or re-
cleotide reductase, was enhanced (but see RNR1, Tablepressed (2-fold) in both the SafA and QAD expression profiles and
2, and discussion below). No other genes known to be(B) genes overexpressed (1.7-fold by one agent (SafA or QAD) and
repressed (1.0-fold) by the other. involved in DNA damage repair were upregulated.
Analysis of Genes Repressed in Both SafAseparated into functional categories, as listed in Table
and QAD Expression Profiles1. The principal categories are identified and discussed
Genes repressed 2-fold after exposure of the yeastbriefly below.
strain CCY333 to SafA or QAD (60 min) can be groupedProteins Involved in Glycolysis
into functional categories, as listed in Table 2. The princi-With the exception of the gene encoding triosephos-
pal categories are identified and discussed brieflyphate isomerase (TPI1, overexpressed 1.6- and 1.5-fold
below.for SafA and QAD, respectively, at 60 min, and 2.0-
Proteins Involved in the Transport of Nutrientsand 1.9-fold, respectively, at 30 min), each of the genes
into the Cellassociated with the conversion of fructose-6-phosphate
Many genes that encode transporter proteins were re-to pyruvate was overexpressed 1.8-fold or greater upon
pressed. These included transporters for amino acids,treatment with SafA at the 60 min time point. Three of
metals, hexoses, ammonia, purines, and oligopeptides.the genes that code for components of pyruvate dehy-
Subunits of the Histone Octamerdrogenase (PDA1, PDA2, and PDB1), an enzyme that
Genes encoding all eight of the histone proteins wereconverts pyruvate to acetyl CoA, also showed enhanced
repressed 2-fold.expression.
Proteins Required for the Synthesis of Fatty AcidsProteins Involved with Protein Degradation
from AcetylCoAThe expression of genes encoding proteins involved in
Genes encoding protein components of the fatty-acidtwo different protein degradation pathways was en-
synthesis pathway (FAS1, FAA3, FAA4) were repressedhanced. Genes encoding proteins, and components of
upon treatment with SafA or QAD (1.8–3.6-fold).the proteasome, in the ubiquitin-mediated proteolytic
Proteins Involved in Glycolysispathway were overexpressed, as were genes encoding
Phosphofructokinase (PFK1) was unique among glyco-
lytic proteins in that both SafA and QAD strongly re-
pressed transcript levels of the gene encoding this en-
zyme (2-fold, 60 min).
Analysis of Genes Expressed to Different Degrees
upon Exposure of the Yeast Strain CCY333
to SafA or QAD
Although the gene expression profiles obtained after
exposure of the yeast strain CCY333 to SafA or QAD
for 60 min were almost identical, analysis of the data
sets did reveal genes that were overexpressed or re-
pressed to different degrees (Table 3). Among these areFigure 4. A Logarithmic Plot of the Ratios of Gene Expression Lev-
els for Each Gene in the Expression Profiles of SafA and QAD genes (such as CUP1, a metallothionein) that encode
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Table 1. Genes Overexpressed in Both SafA and QAD Profiles
Fold Change
Gene Name SafA QAD Protein Function
Glycolysis
FBA1 2.7 2.3 Fructose bisphosphate aldolase II
TDH1 2.5 1.7 Glyceraldehyde-3-phosphate dehydrogenase 1
TDH2 3.8 2.5 Glyceraldehyde-3-phosphate dehydrogenase 2
TDH3 3.2 2.6 Glyceraldehyde-3-phosphate dehydrogenase 3
PGK1 1.8 1.7 Phosphoglycerate kinase
GPM1 2.4 2.1 Phosphoglycerate mutase
ENO1 2.5 2.1 Enolase 1 (2-phosphoglycerate dehydratase)
ENO2 2.5 2.2 Enolase 2 (2-phosphoglycerate dehydratase)
PYK1 2.1 1.6 Pyruvate kinase, catalyzes final step in glycolysis
PDA1 2.1 2.3 Pyruvate dehydrogenase complex E1-alpha subunit
PDA2 1.9 1.8 Pyruvate dehydrogenase complex, E2 component
PDB1 2.0 1.8 Pyruvate dehydrogenase complex, E1-beta subunit
Pentose Phosphate Pathway
RPE1 2.0 1.8 Ribulose-5-phosphate 3-epimerase
Protein Degradation
UBC4 3.0 2.5 Ubiquitin-conjugating (E2) enzyme
UBC1 1.9 2.0 Ubiquitin-conjugating (E2) enzyme
PRE7 2.1 2.2 Proteasome subunit beta6
PRE9 2.0 1.8 Proteasome subunit alpha3
RPN8 2.0 2.2 Non-ATPase subunit of the 26S proteasome complex
AUT7 3.7 3.5 Required for delivery of autophagosomes to vacuole
PEP4 2.0 2.5 Proteinase A
LAP3 1.9 2.2 Aminopeptidase of cysteine protease family
LAP4 1.9 2.7 Aminopeptidase I of the vacuole
PRC1 2.1 2.4 Carboxypeptidase Y, a vacuolar serine protease
CPS1 2.0 1.8 Gly-X carboxypeptidase
Vacuolar H-ATPases
VMA2 2.1 2.0 Vacuolar H-ATPase regulatory subunit
VMA4 2.2 2.2 Vacuolar H-ATPase hydrophilic subunit
Oxidative-Stress Response
SOD1 1.9 1.8 Copper-zinc superoxide dismutase
SOD2 2.3 2.0 Manganese superoxide dismutase
TRX1 2.5 2.3 Thioredoxin I
TRX2 2.4 2.3 Thioredoxin II
HYR1 2.5 2.9 Glutathione peroxidase
TSA1 2.3 2.4 Thioredoxin peroxidase
PRX1 2.9 2.7 Mitochondrial thiol peroxidase
Heat Shock
HSP42 4.1 3.0 Heat shock protein
HSP12 2.8 4.5 Heat shock protein of 12 kDa
HSP10 2.5 2.5 Mitochondrial chaperonin
HSP26 2.4 2.9 Heat shock protein of 26 kDa
SSE1 2.1 1.8 Heat shock protein of the Hsp70 family
SBA1 2.5 2.5 Hsp90 associated cochaperone
Proline Isomerases
CPR6 5.0 2.9 Cyclophilin
CPR3 2.4 2.2 Cyclophilin
CYP2 2.1 3.3 Cyclophilin
CYP5 2.3 1.7 Cyclophilin
FPR1 2.4 2.3 Peptidylprolyl cis-trans isomerase
FPR3 2.2 2.1 Peptidylprolyl cis-trans isomerase
Other Cell-Stress Response
GRE3 2.2 2.3 Aldose reductase with NADPH specificity
GTT1 2.6 3.3 Glutathione transferase
GTT2 1.9 2 Glutathione transferase
PNC1 2.5 2.7 Pyrazinamidase and nicotinamidase
PHO88 2.1 2.2 Inorganic phosphate transport
(continued)
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Table 1. Continued
Fold Change
Gene Name SafA QAD Protein Function
RNA Processing
HRP1 2.4 2.4 Nuclear polyadenylated RNA-binding protein
SBP1 2.1 2.1 Important for rRNA processing
DNA-Damage Response
RNR2 2.0 2.6 Component of ribonucleotide reductase
RNR4 2.3 2.9 Component of ribonucleotide reductase
Amino Acid Metabolism
CYS3 2.2 2.2 Cystathionine gamma-lyase
PRO3 2.1 2.0 Delta-1-pyrroline-5-carboxylate reductase
ARO8 2.1 2.0 Aromatic amino acid aminotransferase I
GCV3 1.9 2.9 Glycine decarboxylase hydrogen carrier
HOM6 2.0 1.8 Homoserine dehydrogenase
ILV6 2.7 2.2 Acetolactate synthase regulatory subunit
Structural Proteins
ARP3 1.9 2.4 Actin-related protein
TPM1 2.1 2.0 Tropomyosin, localized to actin cables
TUB1 2.3 1.9 Tubulin alpha-1 chain
Vesicular Transport
YGR284C 2.7 2.5 Component of COPII-coated vesicles
COF1 2.4 2.4 Cofilin, actin binding and severing protein
Protein Synthesis
TEF2 2.6 2.1 Translation elongation factor EF-1 alpha
MRP8 2.1 2.4 Mitochondrial ribosomal protein
Miscellaneous
CMD1 2.5 2.1 Calmodulin, calcium-binding protein
TFS1 1.9 2.4 Nutrient- and ammonia-response cell cycle regulator
YLR179C 2.1 2.1 Protein with similarity to Tfs1p
BTN2 2.2 2.0 Role in cellular pH homeostasis
IPP1 2.3 2.1 Inorganic pyrophosphatase, cytoplasmic
NCE102 2.4 2.0 Export that lacks classical secretory signal sequences
GUK1 2.2 2.1 Guanylate kinase
ARA1 2 2.2 Subunit D-arabinose dehydrogenase
NTF2 2.6 2.0 Nuclear transport factor
YDL100C 2.0 2.0 Protein with similarity to E. coli ArsA
Time points were taken after 60 min.
proteins associated with the sequestering of metal ions damaging agent NCS (50 M, 1 hr) [34] and the natural
product rapamycin (100 nM, 1 hr) [32], shown to affectand genes (such as AHP1, alkylhydroperoxide reduc-
tase) that encode proteins involved in oxidative-stress nutrient-sensing in yeast, also showed little statistical cor-
relation (	  0.03 and 0.10, respectively).response. No genes overexpressed 1.7-fold after
treatment with either agent (60 min) were repressed
1.7-fold in the profile of the other. Discussion
Deletion of the ergosterol biosynthesis gene ERG6, asStatistical Comparison of the SafA Expression
Profiles with Profiles of Known DNA-Modifying well as the transcription factors PDR1 and PDR3, which
regulate the expression of a network of genes that areAgents and the Natural Product Rapamycin
Comparison of the expression profile (logarithmic plot involved in multidrug resistance, renders yeast suscepti-
ble to growth inhibition by SafA and QAD (IC50  0.9 andof the ratios of gene expression levels, treated:control)
from SafA treatment with profiles obtained from treat- 0.4 M, respectively), suggesting that the resistance of
wild-type yeast to these small molecules is at least inment of the same yeast strain (CCY333) with the known
DNA-modifying agents mitomycin C (10 M, 1 hr, 	  part due to drug permeability/export issues. The avail-
ability of a viable yeast mutant that is sensitive to SafA0.34) and MMS (50 M, 1 hr, 	  0.24) (S.E.S., unpub-
lished data) showed little statistical correlation. Similarly, and QAD has allowed us to conduct DNA microarray
experiments to monitor the effects of drug treatment atcomparison of the SafA profile with profiles obtained from
treatment of the yeast strain BY4743 with the known DNA- the level of transcription in a simple eukaryotic organ-
Chemistry & Biology
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Table 2. Genes Repressed in Both SafA and QAD Profiles
Fold Change
Gene Name SafA QAD Protein Function
Transporters
DIP5 3.3 2.4 Dicarboxylic amino acid permease
VAP1 2.3 2.4 Amino acid permease
BAP2 2.9 2.3 Branched-chain amino acid permease
GNP1 2.5 2.6 High-affinity glutamine permease
PHO84 2.7 2.6 High-affinity inorganic phosphate/H symporter
PTR2 2.7 2.4 Di- and tri-peptide permease
HXT1 2.0 2.3 Low-affinity hexose transporter
HXT4 1.8 2.0 High-affinity glucose transporter
PMA1 1.9 2.5 Plasma membrane H-ATPase
PMA2 2.1 2.8 H-transporting ATPase of the plasma membrane
FCY2 2.9 3.1 Cytosine/purine permease
SSU1 2.7 2.2 Plasma membrane transporter involved in sulfite efflux
TAT2 2.3 2.5 High affinity tryptophan permease
BAP3 2.1 2.3 Valine transporter
FRE1 3.1 2.6 Membrane-associated flavocytochrome
FRE7 2.9 2.0 Protein with weak similarity to Fre1p and Fre2p
STE6 2.0 1.9 ABC transporter
SNQ2 1.9 2.0 Putative ATP-dependent permease
TPO2 1.8 2.6 Polyamine transport protein
TPO3 1.8 2.3 Polyamine transport protein
OPT1 2.2 1.9 Protein member of the oligopeptide transporter family
AQY2 2.7 1.7 Aquaporin water channel protein
MEP3 1.9 1.7 Ammonia permease
Histones
HTA1 2.6 3.1 Histone H2A
HTA2 2.5 2.9 Histone H2A
HTB1 2.0 2.4 Histone H2B
HTB2 2.1 2.5 Histone H2B
HHT1 2.1 2.2 Histone H3
HHT2 2.2 2.3 Histone H3
HHF1 2.0 2.3 Histone H4
HHF2 2.3 2.2 Histone H4
Fatty Acid, Steroid and Amino Acid Metabolism
FAS1 2.8 3.6 Fatty acyl-CoA synthase
FAA3 2.6 2.3 Acyl-CoA synthase
FAA4 1.8 2.1 Long-chain fatty acid-CoA ligase and synthetase 4
GLN1 4.4 6.4 Glutamine synthetase
CPA2 2.8 2.2 Carbamoylphosphate synthetase
ILV5 2.7 3.1 Ketol-acid reductoisomerase
GLY1 2.8 3.5 Threonine aldolase
ASN1 2.0 2.0 Asparagine synthetase
HMG1 2.5 2.7 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
ERG1 2.2 2.2 Squalene monoxygenase
ERG5 2.3 2.6 Cytochrome P450
GPD2 1.8 2.1 Glycerol-3-phosphate dehydrogenase (NAD)
Cell Cycle Control and Cyclins
EGT2 2.2 3.1 Involved in correct timing of cell separation
CLN1 2.4 2.7 G1/S-specific cyclin
CLN3 1.8 2.1 G(sub)1 cyclin
CLB1 2.8 2.6 G2/M-phase-specific cyclin
DNA-Damage Response
RNR1 2.2 2.5 Ribonucleotide reductase large subunit
Glycolysis
PFK2 2.1 2.3 Phosphofructokinase
Protein Synthesis
RPL3 3.2 3.0 Ribosomal protein L3
RPL15A 2.2 2.3 Ribosomal protein L15
RPL15B 2.6 2.7 Ribosomal protein L15
(continued)
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Table 2. Continued
Fold Change
Gene Name SafA QAD Protein Function
Protein Synthesis
RPL4A 2.4 2.3 Ribosomal protein L4
RPL4B 2.5 2.4 Ribosomal protein L4
RPL12A 1.9 2.0 Ribosomal protein L12
DED1 3.0 3.4 ATP-dependent RNA helicase
TIF4631 2.2 2.3 mRNA cap-binding protein (elF4F)
MSS116 2.0 1.7 Mitochondrial RNA helicase
Cell Wall Maintenance
PIR1 2.4 3.2 Protein required for tolerance to heat shock
PIR3 2.2 3.5 Similar to Pir1
SCW11 3.5 3.8 Putative cell wall protein
CHS1 2.0 2.3 Chitin synthase 1
Miscellaneous
BDF1 2.4 2.3 Protein required for sporulation
ALD5 2.6 2.3 Mitochondrial aldehyde dehydrogenase
ALD6 2.9 2.8 Cytosolic acetaldehyde dehydrogenase
FKS1 2.6 3 Component of beta-1,3-glucan synthase
YDL037C 3.3 5.1 Similarity to glucan 1,4-alpha-glucosidase
RPM2 2.0 2.0 Subunit of mitochondrial RNase P
YFR055W 2.7 2.2 Similarity to E. coli cystathionine beta-lyase
HPT1 2.3 2.2 Hypoxanthine Phosphoribosyltransferase
MCD4 2.5 2.4 Glycosylphosphatidylinositol anchor synthesis
GPI13 1.7 2.0 Glycosylphosphatidylinositol biosynthesis
ASH1 2.3 2.2 GATA-type transcription factor
CDC39 2.2 2.5 Negatively regulates basal transcription
NUP100 2.2 2.5 Nuclear pore complex protein
ROX1 2.2 2.0 Site-specific DNA binding protein, repressor
YNR053C 2.0 2.1 Export of 6OS ribosomal subunit from nucleus
SUR1 2.2 2.3 Mannosylated sphingolipids synthesis
RHR2 2.2 2.6 DL-glycerol-3-phosphatase
NOG1 2.2 2.2 Putative nucleolar GTP-binding protein
MNN1 2.1 2.1 Alpha-1,3-mannosyltransferase
MNN2 2.1 2.0 Probable type II membrane protein
HOS3 1.9 2.0 Member of the histone deacetylase family
VID27 2.0 1.8 Fructose-1,6-bisphosphatase import into Vid vesicles
Time points were taken after 60 min.
ism. In order to minimize potential temporal effects and to controls, however, were the same for both agents,
suggesting that the primary effects of the two com-maximize the probability that the profiling data would
represent primary responses to drug treatment, we con- pounds are the same. This conclusion is strengthened
by comparison of the expression profiles from SafAducted incubations for only 1 hr time periods.
The results of whole-genome transcription-profiling treatment with those obtained from the known DNA-
modifying agents mitomycin C and MMS (S.E.S., unpub-experiments conducted with the ERG6/PDR1/PDR3-
deletant (strain CCY333) reveal that extensive modifica- lished data) as well as with profiles obtained from the
DNA-damaging agent NCS [34] and the mechanisticallytion of the expression levels of large numbers of yeast
genes occurs in response to treatment with SafA and unrelated natural product rapamycin [32]. In all cases,
statistical correlations (	-values) fell below 0.35. TheQAD. By comparing the transcription profiles, we were
able to establish that there was a high degree of similar- data may be taken to support the reasonable but un-
proven assertion that transcription-profiling experi-ity in the response of yeast to each agent (0.87 statistical
correlation at 60 min). Differences in the degrees of ments can be used as a tool for analyzing similarities
or differences among cellular response pathways in-overexpression or repression of genes between the pro-
files were few (Table 3), and almost no genes were over- duced by different small molecules and, in a more gen-
eral sense, for evaluating structure-activity relationshipsexpressed in one profile and repressed in the other (Fig-
ure 3B). Those genes that did display differing degrees among bioactive compounds.
Analysis of genes that were overexpressed or re-of expression in profile comparisons point toward al-
tered redox properties of SafA and QAD, which is not pressed to similar degrees in SafA and QAD expression
profiles (Tables 1 and 2) provides a wealth of informationunexpected in light of their quinone/hydroquinone rela-
tionship, and may also reflect a modification of metal- concerning the pathways that are influenced by drug
treatment. The largest group of genes with modifiedion transport in response to drug treatment. Variations
in transcript levels of the great majority of genes relative transcript levels, both in terms of the number of repre-
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Table 3. Genes Expressed to Different Degrees in SafA and QAD Profiles
Fold Change
Gene Name SafA QAD Protein Function
Metal Ion Uptake and Sequestering
CUP1 1.9 1.2 Metallothionein (copper chelatin)
FIT2 2.6 1.5 Possibly involved in iron uptake
FIT3 3.2 2.0 Possibly involved in iron uptake
CTR1 3.2 1.9 Required for high-affinity uptake of copper
Oxidative Stress
AHP1 2.8 1.9 Alkyl hydroperoxide reductase
YBR101C 2.0 1.6 Involved in resistance to H2O2
UTH1 2.3 1.7 Involved in the aging process
Additional Stress Response
DDR2 1.6 2.1 Induced by stresses such as DNA damage
GRE2 1.5 2.0 Induced by osmotic stress
FKB2 1.4 2.0 FKBP (FK506 binding protein), heat shock
SSA2 2.1 1.5 Member of 70 kDa heat shock protein family
SSA4 1.7 1.0 Chaperone of the HSP70 family
Protein Synthesis
HYP2 2.1 1.4 Translation initiation factor elf-5A
TEF4 2.2 1.5 Translation elongation factor EF-1gamma
RPS25A 2.0 1.5 Ribosomal protein S25A
RPLA0 2.5 1.8 Acidic ribosomal protein A0
YKL056C 2.1 1.4 Possibly involved in cytoplasmic ribosome function
Nonclassical Export
NCE103 1.5 2.7 Export that lacks classical secretory signal sequences
Unknown Function
YKL136W 2.3 1.1 Unknown function
YHL005C 1.2 4.1 Unknown function
YJL182C 1.7 3.3 Unknown function
YJL217W 1.8 3.1 Unknown function
YDL124W 1.6 3.1 Unknown function
Time points were taken after 60 min.
sentatives and the magnitude of expression modifica- PDB; see Table 1). Transcript levels of genes of the
tricarboxylic acid cycle and the glyoxylate cycle, path-tion, were those involved in glycolysis. Glycolysis trans-
forms glucose into two molecules of pyruvate and ways utilizing acetyl CoA, were not modified, however,
and several genes directing the synthesis of fatty acidsprovides much of the energy for yeast growing in glu-
cose-rich media [43]. Interestingly, although the majority from acetyl CoA were repressed (FAS1, FAA3, FAA4,
Table 2). Unlike treatment with hydrogen peroxide [45]of the genes of the glycolytic pathway were overex-
pressed, with the three isoforms of glyceraldehyde-3- or rapamycin [32], treatment with SafA and QAD does
not appear to induce the diauxic shift [29] in the timephosphate dehydrogenase upregulated to the greatest
degree, phosphofructokinase, the gene coding for the period examined.
Both SafA and QAD induced a series of genes associ-principal rate-limiting enzyme in glycolysis, was sub-
stantially downregulated (PFK2, 2.1- and 2.3-fold for ated with protein degradation (Table 1). Expression of
several genes encoding subunits of the proteasomeSafA and QAD, respectively) [44]. This discontinuity in
expression modification is intriguing and may signal the (PRE7, PRE9, RPN8) was enhanced, as was the expres-
sion of genes encoding enzymes of the ubiquitin-medi-occurrence of a primary interaction between SafA (or
QAD) with an enzyme or enzymes of the glycolytic path- ated proteolytic pathway (UBI4, UBC4, Table 1) [46, 47].
The expression profiles also provided evidence of anway. It may also represent a secondary response, per-
haps the diversion of glucose metabolism toward the increased role in treated cells of the process of autoph-
agy, the nonspecific bulk flow transport pathway thatpentose phosphate pathway, although ribulose-5-phos-
phate 3-epimerase (RPE1) was the only gene in this delivers cytosolic material and even whole organelles
to the vacuole for degradation [48, 49]. The gene AUT7,pathway that was overexpressed to a notable degree
in both profiles (SafA and QAD, 2.0- and 1.8-fold, respec- encoding a protein that attaches the vesicles known as
autophagosomes to the microtubules for delivery to thetively, at 60 min). In addition to genes of the glycolytic
pathway, three of the genes encoding pyruvate dehydro- vacuole [50], is greatly upregulated (3.7- and 3.5-fold
for SafA and QAD, respectively). Members of the heat-genase, catalyzing the transformation of pyruvate into
acetyl CoA, were overexpressed (PDA1, PDA2, and shock protein family have also been shown to be in-
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volved in the uptake of cytosolic proteins into the vacu- that of RNR2 and RNR4, which suggests that drug treat-
ment leads to a lower population of cells in this phaseole; expression of two of these genes (SSE1 and SSA2)
was enhanced (Tables 1 and 3) [51]. Genes encoding of the cell cycle with RNR1 relative to controls [40]. In
this regard, it is significant that genes encoding the eightseveral different proteases involved in the degradation
of proteins in the vacuole also exhibited enhanced ex- histone proteins were also strongly repressed in both
profiles. These genes have been shown to be tightlypression levels (LAP4, PEP4, CPS1, and PRC1; Table
1). In addition, we observed increased expression of regulated by the cell cycle and to display high levels
only during S phase; their mRNA abundance is verygenes encoding vacuolar H-ATPases, required to
maintain the acidity of the vacuole (VMA3, VMA4, and low during G1 and G2 phases [58]. These observations
suggest that SafA and QAD may influence the cell cycleVMA13; Table 1) [52]. Although we see little evidence
of transcriptional activation of the carbon starvation [29] after S phase.
In view of fact that treatment of the mutant yeast strainand nitrogen discrimination pathways (glutamine syn-
thetase, GLN1, is actually downregulated 4.3- and 6.4- with SafA and QAD led to rapid depletion of mRNA
levels, it is noteworthy that the gene HRP1, encoding afold in the SafA and QAD profiles, respectively, at 60
min) [53], more than 20 genes encoding proteins for protein responsible for mRNA processing, was upregu-
lated in both profiles (2.4-fold), as was SBP1, a genenutrient transport were significantly repressed (Table
2). Among these are permeases for amino acids (DIP5, important in rRNA processing. It is not clear from the
data at hand if mRNA depletion is a primary or secondaryBAP2, BAP3, GNP1, SCM2, and VAP1), ammonia
(MEP3), protons (PMA1, PMA2), purines (FCY2), water consequence of drug treatment, but it is clearly a signifi-
cant component of the drug-induced cellular response.(AQY2), and inorganic phosphate (PHO84). It is possible
that this global repression of transporter proteins may
represent an attempt to prevent further import of a toxic Significance
drug substance. As a response to a reduced influx of
nutrients, cellular contents may then be redistributed Identification of an S. cerevisiae strain (CCY333) that
is sensitive to treatment with SafA and QAD has al-through the process of autophagy, which is often caused
by nutrient starvation, as well as oxidative stress. The lowed us to evaluate and compare the genetic re-
sponses to drug treatment by whole-genome tran-drug efflux proteins SNQ1, SNQ2, and YPR156C, other
genes associated with small-molecule import and ex- scription profiling (DNA microarray analysis). In this
way we have identified many of the significant geneticport, were repressed in both profiles (somewhat surpris-
ingly), whereas overexpression of genes encoding the response pathways (upregulation of genes involved in
glycolysis, protein degradation pathways, and oxida-nonclassical export proteins NCE102 and NCE103 was
enhanced significantly. tive-stress response; downregulation of genes encod-
ing transporter proteins, histones, proteins involvedIn addition to the functional categories described,
several genes associated with oxidative-stress re- in fatty-acid synthesis, two RNA-processing enzymes,
and PFK2, the principal rate-limiting enzyme in glycol-sponse were upregulated to similar degrees in profiles
of both SafA and QAD (Table 1), and a few genes of this ysis). Perhaps of equal importance, we have found
that known DNA-damage response pathways are notcategory were more strongly upregulated in the SafA
profile (Table 3). SafA and QAD are nominally at different transcriptionally modified, suggesting that the primary
mechanism of action of SafA (and QAD) may not in-ends of a redox spectrum (SafA being more oxidizing),
although this distinction may be obfuscated by the pos- volve known DNA-damage pathways. In addition to
providing these insights into the effects of treatment ofsible interconversion of quinone and hydroquinone
forms within the cell by redox processes. Although over- a simple eukaryotic organism with the natural product
saframycin A (SafA), the profiling data have allowedexpression of genes associated with oxidative stress
was one of the most extensive transcriptional responses us to conclude that activity-directed synthesis optimi-
zation produced an agent (QAD) that not only showedin terms of the number of genes that were upregulated,
it was not the only form of stress response evident upon greater antiproliferative activity but also affected the
same biochemical pathways as the lead structure,drug treatment. Many of the heat-shock proteins, as
well as proline isomerases and GRE3, a gene induced showing that transcriptional profiling experiments can
by osmotic stress, were overexpressed [54, 55]. provide a valuable tool in evaluating structure-activity
One of the more surprising findings from analysis of relationships in a bioactive-compound series [26].
the profiling data, in light of prior work showing that
Experimental ProceduresSafA can reversibly alkylate guanine residues of duplex
DNA in vitro, was the lack of transcriptional upregulation
Yeast Strains and Growth of Cultures
of any known DNA-damage repair proteins [56]. Al- Saccharomyces cerevisiae strains BY4743 (diploid; BY4741/BY4742
though enhanced expression was observed for RNR2 [MATa his3
1 leu2
0 lys2
0 ura3
0]) and CCY333 (MATa ura3-1
and RNR4, genes encoding components of ribonucleo- leu2-3,11 his3-11 trp1-1 can1-100 ade2-1 bar1-1 erg6
::TRP1
pdr3
::HIS5 pdr1
::KAN [isogenic with W303 strain backgroundtide reductase (required for deoxyribonucleotide pool
(W303-1a; R. Rothstein, Columbia University, New York)]) were usedmaintenance during DNA-damage repair and DNA repli-
for these studies. For growth-inhibition and expression-profiling ex-cation), RNR1, the gene encoding the major subunit of
periments, 5 ml of YPD medium (2% glucose/2% peptone/1% yeastribonucleotide reductase, was significantly repressed
extract) was inoculated with a single colony of the specified yeast
(2.2- and 2.5-fold for SafA and QAD, respectively, at 60 strain. The cells were grown at 30C on a shaker (275 rpm) for 24
min) [57]. Peaking in G1 to S phase, the expression of hr, and the growth medium was diluted 100-fold in YPD medium to
give two separate cultures, each with an absorbance (A600) of 0.07.RNR1 is more strongly regulated by the cell cycle than
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Incubation continued until the absorbance (A600) of the culture was than three standard deviations above the average background inten-
sity (calculated over the entire array) were considered for further0.3. The cells were then treated with solutions of SafA or QAD in
DMSO to give a final concentration of drug equal to 10 M (the analysis in order to avoid errors due to low signal intensity. The
ratio (total signal from all Cy3 channels)/(total signal from all Cy5maximum concentration of DMSO in the total culture was 1% v:v). An
equal volume of DMSO was added to the control cultures. Aliquots of channels) was calculated to provide a scaling factor for normaliza-
tion between the channels; this factor was then applied uniformlythe culture medium (40 ml) were harvested at the indicated times.
Cells from each aliquot were pelleted by centrifugation (2500  g) to each spot. Only genes with reproducible (2 hybridizations) ex-
pression differences of 1.7-fold or more were considered in ourfor 5 min at 30C, then were flash-frozen in liquid nitrogen and stored
at 80C for later extraction of RNA. Each experiment with SafA or analysis. The Yeast Protein Database (YPD) [61] and the GeneSpring
software package (Silicon Genetics, Redwood City, CA) wereQAD was carried out in duplicate.
used for data analysis. Data sets from profiling experiments can
be obtained at http://www.chem.harvard.edu/groups/myers/Growth Inhibition Studies
myers_research_group.htm.Exponentially growing yeast cultures were diluted with YPD medium
(2% glucose/2% peptone/1% yeast extract) to give a solution with
Statistical Analysisan absorbance (A660) of 0.06. Aliquots (135 l ) of the diluted cell
The correlation coefficient was calculated from the following for-cultures were then dispensed into each well of flat-bottomed 96-
mula:well plates [37]. Solutions of SafA and QAD (50 mM DMSO) were
diluted serially with YPD medium and DMSO to afford solutions of
each drug varying incrementally over a range of concentrations 	(X,Y) 
cov(X, Y)
Y · X(0.056–370 M, total concentration of DMSO, 20% v:v). Wells con-
taining yeast cultures were treated with 15 l aliquots of the drug where,
solutions; 15 l aliquots of YPD medium (20% v:v DMSO) were
added to the control wells. Each concentration value for each drug
2X 
1
n
 (Xi  x)2was represented in triplicate on the plate, and each experiment
was conducted twice. Plates were incubated for 22 hr at 30C. The
absorbance (A660) of each well was read with a SPECTRAmax PLUS
2Y 
1
n
 (Yi  Y)2384 spectrophotometer (Molecular Devices, Palatine, IL). Control
wells gave a final absorbance (A660) of 0.8. Inhibition (%) was calcu-
lated according to the following formula: %  100  (C  T)/C, The GeneSpring software package (Silicon Genetics, Redwood City,
where T is the absorbance of the well containing the test compound CA) was used for P value determination.
minus the absorbance of a sample of YPD medium (containing 20%
v:v DMSO) alone and C is the absorbance of the control well minus Acknowledgments
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